marked.bio

Company

Xcovery Holdings

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ensartinib 1crizotinib 1

Trials

2 of 3 trials shown

  1. eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Active, not recruiting Phase 3 Xcovery Holdings Started 2016Primary completion 2025-12 NCT02767804

    ensartinib FDAcrizotinib FDA EU

    …age IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive by an FDA-approved assay performed centrally.

    ALK fusionNon-small Cell Lung Cancer

  2. BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

    Not yet recruiting Phase 1/2 Xcovery Holdings Started 2026Primary completion 2028-01 NCT05393466

    BPI-361175

    …lly confirmed diagnosis of inoperable locally advanced or recurrent/metastatic NSCLC with EGFR mutations.

    EGFR exon 19 deletion / L858RNon-small Cell Lung Carcinoma